13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
![](/mel/img/quote_button.gif) |
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
94,380 |
12.07.24 17:35:48 |
+0,580 |
+0,62% |
0,000 |
0,000 |
94,510 |
94,380 |
![](/mel/img/quote_button.gif) |
Regeneron Pharmaceuticals |
881535 |
NASDAQ |
1.100,050 |
12.07.24 23:16:43 |
+20,320 |
+1,88% |
1.065,000 |
1.100,590 |
1.092,080 |
1.100,050 |